Welcome to our dedicated page for Kadmon Holdings news (Ticker: KDMN), a resource for investors and traders seeking the latest updates and insights on Kadmon Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kadmon Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kadmon Holdings's position in the market.
Kadmon Holdings (NYSE:KDMN) announced that CEO Harlan W. Waksal will present at several upcoming virtual investor conferences. Key presentations include:
- H.C. Wainwright Conference: September 14, 2020, 11:00 a.m. ET
- Cantor Fitzgerald Conference: September 15, 2020, 1:20 p.m. ET
- Oppenheimer Summit: September 21, 2020, 2:30 p.m. ET
Waksal will also participate in investor meetings at the Citi and Morgan Stanley conferences. Live audio webcasts will be available on Kadmon's website.
Kadmon Holdings, Inc. (NYSE: KDMN) announced the appointment of Nancy Miller-Rich to its Board of Directors. With 35 years in the pharmaceutical industry, her experience includes leadership roles at Merck and Schering-Plough. As the company prepares for key milestones, including the NDA submission for belumosudil for chronic graft-versus-host disease (cGVHD), her expertise in global business development is expected to enhance Kadmon's strategies. Belumosudil has received Breakthrough Therapy Designation and is under review for cGVHD treatment.
Kadmon Holdings, Inc. (NYSE:KDMN) announced the appointment of Nancy Miller-Rich to its Board of Directors, bringing over 35 years of pharmaceutical industry experience. Her past roles include Senior Vice President at Merck, where she focused on global business development. The company anticipates Miller-Rich's insights will enhance its strategic plans, particularly regarding the NDA submission for belumosudil, a treatment for chronic graft-versus-host disease. Belumosudil has received Breakthrough Therapy and Orphan Drug designations from the FDA.